Chimerix Remains Positive As it Assesses Steps Forward

After a late-stage failure, Chimerix is closing down two other late-stage trials and reassessing the path forward for its lead compound. Yet, management struck a positive tone on a conference call with analysts, indicating other formulations and better physician education could remedy the issues.

Chimerix stock tanked in late December when the company announced that its lead compound brincidofovir failed to meet its primary...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category